Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215889 | 0.88 | SMN1; SMN2 (0.57) | HPGDSMN1; SMN2CYP2C19MAPTALOX12 | |
| SCHEMBL9495103 | 0.85 | SMN1; SMN2 (0.71) | HPGDSMN1; SMN2CYP2C19MAPTALOX12 | |
| SCHEMBL19016263 | 0.85 | KDM4E (0.56) | HPGDSMN1; SMN2ALDH1A1KDM4EFADS1 | |
| SCHEMBL12569855 | 0.83 | FADS1 (0.55) | HPGDSMN1; SMN2ALDH1A1KDM4EFADS1 | |
| SCHEMBL6409278 | 0.83 | POLB (0.63) | SMN1; SMN2CYP2C19MAPTMAPK1ALDH1A1 | |
| SCHEMBL4002308 | 0.81 | SMN1; SMN2 (0.55) | HPGDSMN1; SMN2MAPTMAPK1HTT | |
| SCHEMBL13547747 | 0.81 | FADS1 (0.54) | HPGDSMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL11795655 | 0.81 | SMN1; SMN2 (0.63) | HPGDSMN1; SMN2CYP2C19MAPK1ALDH1A1 | |
| SCHEMBL967250 | 0.81 | FADS1 (0.57) | HPGDALDH1A1KDM4EFADS1NLRP3 | |
| SCHEMBL2091354 | 0.81 | FADS1 (0.56) | HPGDMAPK1ALDH1A1FADS1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | HPGD 4110/4885SMN1; SMN2 4581/4885CYP2C19 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.